Ionis Pharmaceuticals (IONS) Q3 2025 Earnings
How Did IONS Stock React to Q3 2025 Earnings?
S&P 500 over the same 30 days: −1.04%.
Did IONS Beat Earnings? Q3 2025 Results
Yes. Ionis Pharmaceuticals reported Q3 2025 earnings of $-0.80 a share on Oct 29, 2025, beating the $-1.05 consensus estimate by 24.0%. Revenue was $157.0M against a $130.5M estimate.
Ionis Pharmaceuticals delivered a convincing double beat in Q3 2025, with the RNA medicines specialist reporting a net loss of $0.80 per share against a consensus estimate of $1.05, a 23.99% positive surprise, while revenue of $157.00 million topped expectations by 20.30% and climbed 17.3% year-over-year. The standout driver was TRYNGOLZA, the company's recently launched cardiovascular drug, which generated $32.00 million in net product sales during the quarter, a nearly 70% jump over the prior quarter, helping push commercial revenue up 53% year-over-year to $116.00 million. CEO Brett Monia characterized the period as a "watershed moment," a descriptor the numbers broadly support. Royalties from SPINRAZA and WAINUA contributed an additional $76.00 million, further reinforcing the revenue mix. Management responded to the momentum by raising full-year 2025 revenue guidance to $875.00 million to $900.00 million, up from the prior range of $825.00 million to $850.00 million, and now targets cash flow breakeven by 2028 as its commercial portfolio continues scaling.
- TRYNGOLZA net product sales grew nearly 70% quarter-over-quarter to $32 million in its third full quarter on market
- Commercial revenue increased 53% year-over-year driven by TRYNGOLZA sales and higher royalty revenue
- Total revenue increased 17% year-over-year
- DAWNZERA approved by FDA in August 2025 with U.S. launch underway and off to encouraging start
- TRYNGOLZA approved in the EU for FCS with Sobi anticipating Q4 2025 launch
“The third quarter was a watershed moment for Ionis, as we made important progress advancing our Ionis-owned medicines. With two independent launches now underway, and two more anticipated in 2026, we are delivering on our goal to bring a steady cadence of new medicines to people in need.”
Ionis Pharmaceuticals CEO, on the earnings call
What Was Ionis Pharmaceuticals's Outlook in Q3 2025?
Ionis raised its full-year 2025 financial guidance: total revenue now expected at $875–$900 million (up from $825–$850 million), TRYNGOLZA net product sales of $85–$95 million (up from $75–$80 million), non-GAAP operating loss of $275–$300 million (improved from $300–$325 million), and cash/investments expected above $2.1 billion (up from ~$2.0 billion). The company anticipates 2026 U.S. launches of olezarsen in severe hypertriglyceridemia and zilganersen in Alexander disease. Management expects growth in product revenues coupled with partner revenues will position Ionis to achieve cash flow breakeven in 2028 and generate substantial sustainable positive cash flow thereafter.
IONS YoY Financials
| Metric | Q3 2025 | Q3 2024 | Year over year |
|---|---|---|---|
| Revenue | $157.0M | $133.8M | +17.3% |
| Operating Income | −$160.0M | −$173.2M | −7.6% |
| Net Income | −$129.0M | −$119.3M | +8.2% |
IONS Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.